Episodes (Page 17)
✨
FDA leaders' pharma CEO tour may face scrutiny.
✨
FDA regulatory shifts and market dynamics impact drug development.
✨
Novo Nordisk CEO exits; biopharma's US economic impact quantified.
✨
Novavax's new COVID-19 vaccine receives a limited label.
✨
Commit Biologics targets serious diseases using the complement system.
Mikkel Wandahl Pederson
✨
Korean biopharma deals face declining ROI due to market instability.
✨
Volker Spitzer discusses validating real-world evidence (RWE) for regulators.
Volker Spitzer
✨
Trump's executive order on drug pricing is mostly rhetoric.
✨
Zai Lab discusses PD-1/IL-12 bispecific and ADC programs.
✨
Industry presents its case to Trump regarding drug pricing.
✨
Vinay Prasad appointed director of FDA's biologics center.
Vinay Prasad
✨
AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs.
✨
Volker Spitzer explains the basics of real-world evidence (RWE).
Volker Spitzer
✨
Anil Matai discusses India's evolving intellectual property regime.
Anil Matai
✨
FDA Commissioner directed assistant to take over Novavax vaccine review.
✨
FDA staff cuts' potential impact on biopharma M&A discussed.
Alan Minsk
Andrew Goodman
Daniel Teper
✨
BIO-Europe 2025 recap: trends in early-stage deal-making.
Carolyn Hall
Trajko Spasenovski
✨
CNS and I&I analysts discuss highlights from AAN 2025.
Istafa Armughan
Joseph Jacob
Wen-Yu Huang
✨
Aragen CEO discusses NIH funding cuts and biotech challenges.
Manni Kantipudi
✨
Top-selling drugs of 2024 and Lilly's diabetes trial win.